RxDoctor Payments Data

Terrence Li, MD

Neurology · Brighton, MANPI 1144484619

Payments from drug & device makers

$1,359in general payments, 2019–2025

Across 69 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$282
  • Pfizer$217
  • AbbVie$161
  • Teva Pharmaceuticals USA, Inc.$140
  • Livanova USA, Inc.$138
  • Biohaven Pharmaceutical Holding Company Ltd.$130
  • plus $291 from 10 others

What the payments were for

  • Consulting fees$15011%
  • Food & beverage$1,20989%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,359 in reported general payments places this provider in the 55th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$87,106
Medicare patients
352
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate14$23,908
Lamotrigine OdtLamotrigine12$4,672
Gabapentin158$3,453
Memantine Hcl57$3,192
Levetiracetam60$3,032
Carbamazepine ErCarbamazepine17$2,568
Lacosamide36$2,555
Donepezil Hcl196$2,126
Galantamine Hbr14$1,659
Carbidopa-LevodopaCarbidopa/Levodopa78$1,533
Quetiapine Fumarate47$1,478
Lamotrigine27$1,376
Phenytoin Sodium Extended25$1,271
Pregabalin40$1,157
Duloxetine Hcl15$944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$217$23,90814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 761 neurology providers in Massachusetts.

Other neurology in Brighton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →